CN110118841B - Method for constructing HPLC (high Performance liquid chromatography) characteristic spectrum of liver and gallbladder clearing oral liquid - Google Patents
Method for constructing HPLC (high Performance liquid chromatography) characteristic spectrum of liver and gallbladder clearing oral liquid Download PDFInfo
- Publication number
- CN110118841B CN110118841B CN201910496854.6A CN201910496854A CN110118841B CN 110118841 B CN110118841 B CN 110118841B CN 201910496854 A CN201910496854 A CN 201910496854A CN 110118841 B CN110118841 B CN 110118841B
- Authority
- CN
- China
- Prior art keywords
- solution
- high performance
- performance liquid
- liquid chromatography
- oral liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
The invention relates to the technical field of Chinese patent medicine quality control, in particular to a method for constructing an HPLC (high performance liquid chromatography) characteristic spectrum of an oral liquid for treating liver and gallbladder diseases. The construction method comprises the following steps: measuring the test solution and the reference solution by high performance liquid chromatography; the conditions of the high performance liquid chromatography are as follows: a C18 chromatography column; acetonitrile is taken as a mobile phase A, and phosphoric acid aqueous solution with the mass percentage of 0.05 percent to 0.15 percent is taken as a mobile phase B for gradient elution. The method can comprehensively control the product quality, ensure the safety and effectiveness of the product, overcome the defects of the detection method in the prior art, avoid the singleness and one-sidedness of quality control, and has the characteristics of convenience, rapidness, stability, precision, good reproducibility and the like.
Description
Technical Field
The invention relates to the technical field of Chinese patent medicine quality control, in particular to a method for constructing an HPLC (high performance liquid chromatography) characteristic spectrum of an oral liquid for treating liver and gallbladder diseases.
Background
The liver and gall dual-effect oral liquid is prepared from 8 Chinese medicinal materials of bear gall powder, moutan bark, barbat skullcap, pilose asiabell root, Chinese angelica root, ligustrum japonicum, eaglewood and malt. Has the effects of clearing heat, promoting bile flow, and regulating qi and blood. Can be used for the adjuvant treatment of hypochondriac pain, dry mouth, bitter taste, anorexia, and asthenia caused by damp-heat in liver and gallbladder and qi and blood disorder.
The detection standard of the liver and gallbladder clearing oral liquid is set in the national drug standard, and the standard number is as follows: WS-5124(B-0124) -2014Z. The standard comprises thin layer identification items of bear gall powder, herba Scutellariae Barbatae and radix Angelicae sinensis and content determination item of paeonol. The quality standard only controls a qualitative and quantitative detection method of one medicine, and a method for comprehensively controlling the product quality is lacked.
The prior publications only disclose methods for measuring the content of paeonol. For example, in "HPLC determination of paeonol in gandan shuangqing oral liquid" published in 2006, the content detection method of paeonol in oral liquid is disclosed, which comprises the following steps:
chromatographic conditions are as follows:
shimadzu VP-ODS C18 chromatographic column (250 mm. times.4.6 mm, 5 μm) with methanol-0.4% phosphoric acid aqueous solution (60:40) as mobile phase; a detection side wavelength of 274 nm; the column temperature is 25 ℃, and the number of theoretical plates is not lower than 4000 calculated according to paeonol. The degree of separation was l.83 and the tailing factor was 1.02. Under the condition, the paeonol and other substances in the sample can be well separated, and the negative liquid has no interference.
Paeonol reference substance, sample and negative reference solution (except cortex moutan in the prescription, making into oral liquid without cortex moutan by the same method as the oral liquid preparation method, and making into negative solution by the same method as the sample preparation method).
Preparation of control solutions:
precisely weighing 2.16mg of paeonol reference substance, adding methanol to dissolve, and diluting to a volume of 10mL to obtain paeonol reference substance solution.
Preparation of a test solution:
precisely sucking 10mL of the product, placing in a separating funnel, extracting with diethyl ether for 4 times, each time 10mL, mixing diethyl ether solutions, and naturally volatilizing. The residue was dissolved in an appropriate amount of methanol and quantitatively transferred to a 100mL measuring flask, diluted to the mark with methanol, and shaken up to give a sample solution.
Therefore, it is necessary to develop a method for detecting the content of multiple active ingredients in the liver and gallbladder clearing oral liquid, so as to analyze and detect the group characteristics of multiple batches of samples, judge the quality difference among product batches and monitor the product quality comprehensively; can also trace the source and find problems in the process operation and the raw medicinal materials.
Disclosure of Invention
In view of the above, the invention provides a method for constructing an HPLC (high performance liquid chromatography) characteristic spectrum of an oral liquid for treating liver and gallbladder diseases. The method can comprehensively control the product quality, ensure the safety and effectiveness of the product, overcome the defects of the detection method in the prior art, avoid the singleness and one-sidedness of quality control, and has the characteristics of convenience, rapidness, stability, precision, good reproducibility and the like.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides a method for constructing an HPLC (high performance liquid chromatography) characteristic spectrum of an oral liquid for treating liver and gallbladder diseases, which comprises the following steps of:
measuring the test solution and the reference solution by high performance liquid chromatography;
the conditions of the high performance liquid chromatography are as follows: a C18 chromatography column; taking acetonitrile as a mobile phase A, taking a phosphoric acid aqueous solution with the mass percentage of 0.05-0.15% as a mobile phase B, and carrying out gradient elution; the procedure for gradient elution was:
preferably, the mobile phase B is a phosphoric acid aqueous solution with the mass percentage of 0.1%.
Preferably, the C18 column has a column length of 25cm, an inner diameter of 4.6mm, and a particle size of 5 μm.
Preferably, the C18 column is a Wondacract ODS C18 column.
Preferably, the detection wavelength of the high performance liquid chromatography is 230-260 nm.
Preferably, the detection wavelength of the high performance liquid chromatography is 245 nm.
Preferably, the column temperature of the high performance liquid chromatography is 30 to 40 ℃.
Preferably, the column temperature of the high performance liquid chromatography is 35 ℃.
Preferably, the flow rate of the high performance liquid chromatography is 0.9 to 1.1 mL/min.
Preferably, the flow rate of the high performance liquid chromatography is 0.9 mL/min.
Preferably, the sample amount of the reference solution or the sample solution is 5 to 15. mu.L.
Preferably, the sample amount of the reference solution or the test solution is 10. mu.L.
Preferably, the reference solution comprises gallic acid solution, paeoniflorin solution, paeonol solution, ferulic acid solution, scutellarin solution, specnuezhenide solution and linalool solution.
Preferably, the solvent of the reference solution is methanol, and the mass volume percentage concentration of the reference solution is 0.08-0.12 mg/mL.
Preferably, the mass volume percentage concentration of the reference substance solution is 0.1 mg/mL.
In the invention, the test solution is stock solution of the liver and gallbladder clearing oral liquid or diluent of the liver and gallbladder clearing oral liquid.
The diluent of the liver and gallbladder clearing oral liquid is the liver and gallbladder clearing oral liquid diluted by water, and the volume percentage content of the liver and gallbladder clearing oral liquid in the diluent of the liver and gallbladder clearing oral liquid is not less than 40%.
Preferably, the volume percentage content of the liver-gallbladder double-clear oral liquid in the diluent of the liver-gallbladder double-clear oral liquid is 80%.
The invention provides a method for constructing an HPLC (high performance liquid chromatography) characteristic spectrum of an oral liquid for treating liver and gallbladder diseases. The construction method comprises the following steps: measuring the test solution and the reference solution by high performance liquid chromatography; the conditions of the high performance liquid chromatography are as follows: a C18 chromatography column; acetonitrile is taken as a mobile phase A, and phosphoric acid aqueous solution with the mass percentage of 0.05 percent to 0.15 percent is taken as a mobile phase B for gradient elution. The invention has the following technical effects:
the detection method can simultaneously analyze and detect the group characteristics of multiple batches of samples, judge the quality difference among product batches and comprehensively monitor the product quality. Can also trace the source and find problems in the process operation and the raw medicinal materials.
The method can comprehensively control the product quality, ensure the safety and effectiveness of the product, overcome the defects of the detection method in the prior art, avoid the singleness and one-sidedness of quality control, and has the characteristics of convenience, rapidness, stability, precision, good reproducibility and the like.
The characteristic spectrum of the test sample shows 15 characteristic peaks, wherein 7 peaks have the same retention time with the corresponding reference object peak. The peak corresponding to the reference material peak of specnuezhenide is the S peak, and the relative retention time of other peaks should be within + -5% of the specified value. The specified values are: 0.16 (peak 1), 0.20 (peak 2), 0.21 (peak 3), 0.42 (peak 4), 0.58 (peak 5), 0.62 (peak 6), 0.72 (peak 7), 0.75 (peak 8), 0.81 (peak 9), 0.92 (peak 10), 0.96 (peak 11), 1.00 (peak 12), 1.45 (peak 13), 1.52 (peak 14), 1.71 (peak 15).
The invention establishes 10 batches of HPLC characteristic spectrums of the liver-gallbladder double-clear oral liquid, and obtains the HPLC standard characteristic spectrum of the liver-gallbladder double-clear oral liquid consisting of 15 characteristic peaks by adopting the analysis of 2004A edition of 'Chinese medicine chromatogram fingerprint similarity evaluation system' of the State Committee of pharmacopoeia. The No. 1 peak is gallic acid, the No. 5 peak is paeoniflorin, the No. 6 peak is linalool, the No. 8 peak is ferulic acid, the No. 11 peak is scutellarin, the No. 12 (S) peak is specnuezhenide, and the No. 15 peak is paeonol. The 15 characteristic peaks were assigned: the chromatographic peaks belonging to the tree peony bark are 4, namely peaks 1, 4, 5 and 15; the chromatographic peaks belonging to the sculellaria barbata are 3, namely No. 9, No. 10 and No. 11 peaks respectively; the chromatographic peaks belonging to the glossy privet fruit are 3, namely No. 12, No. 13 and No. 14 peaks respectively; the chromatographic peaks attributed to angelica sinensis are 1, and are No. 8 peaks; the chromatographic peaks attributed to eaglewood are 2 peaks, namely, 6 peaks and 7 peaks.
Drawings
FIG. 1 shows a common pattern diagram of 10 batches of Gandanshuangqing oral liquid feature maps;
FIG. 2 shows a comparative characteristic spectrum of Gandanshuangqing oral liquid.
Detailed Description
The invention discloses a method for constructing an HPLC (high performance liquid chromatography) characteristic spectrum of an oral liquid for treating liver and gallbladder diseases, and a person skilled in the art can appropriately improve process parameters by referring to the content. It is expressly intended that all such similar substitutes and modifications which would be obvious to one skilled in the art are deemed to be included in the invention. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the methods and applications described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of this invention without departing from the spirit and scope of the invention.
The method for constructing the characteristic spectrum of the liver-gallbladder clearing oral liquid comprises the following steps:
chromatographic conditions and System suitability test by using Wndacrat ODS C18 chromatographic column (column length 25cm, inner diameter 4.6mm, particle size 5 μm); acetonitrile is taken as a mobile phase A, 0.1 percent phosphoric acid solution is taken as a mobile phase B, and gradient elution is carried out according to the specification in the following table; the detection wavelength is 230-260 nm; the column temperature is 30-40 ℃; the flow rate is 0.9-1.1 mL/min; the theoretical plate number is not less than 6000 calculated according to the specnuezhenide peak.
Preparation of reference solutions: taking appropriate amount of gallic acid, paeoniflorin, paeonol, ferulic acid, scutellarin, specnuezhenide, and linalool as reference substances, precisely weighing, and respectively making into solution containing 0.1mg per 1mL with methanol.
Preparation of a test solution: precisely measuring 10-20 mL of the product, placing the product in a 20-25 mL measuring flask, diluting the product to a scale with water, shaking up, filtering, and taking a subsequent filtrate as a test solution.
The determination method comprises the following steps: and precisely absorbing 5-15 mu L of reference substance solution and test solution respectively, injecting into a liquid chromatograph, measuring, and recording a chromatogram map.
Reagents or instruments used in the method for constructing the HPLC characteristic spectrum of the liver and gallbladder clearing oral liquid provided by the invention can be purchased from the market.
The invention is further illustrated by the following examples:
example 1 construction method of characteristic spectrum of Gandanshuangqing oral liquid
1 chromatographic conditions and System suitability test Using Wndacrat ODS C18 column (column length 25cm, inner diameter 4.6mm, particle size 5 μm); acetonitrile is taken as a mobile phase A, 0.1 percent phosphoric acid solution is taken as a mobile phase B, and gradient elution is carried out according to the specification in the following table; the detection wavelength is 245 nm; the column temperature was 35 ℃; the flow rate is 0.9 mL/min; the theoretical plate number is not less than 6000 calculated according to the specnuezhenide peak.
2 preparing reference solution taking appropriate amount of gallic acid, paeoniflorin, paeonol, ferulic acid, scutellarin, specnuezhenide, and linalool, precisely weighing, and respectively making into solution containing 0.1 mg/1 mL with methanol.
3 preparation of test solution 20mL of the product is precisely measured, placed in a 25mL measuring flask, diluted to the scale with water, shaken, filtered, and the subsequent filtrate is taken as the test solution.
And 4, precisely absorbing 10 mu L of reference solution and test solution respectively by the measuring method, injecting the solution into a liquid chromatograph, measuring, and recording a chromatogram map to obtain the product.
Test examples example 1 methodological examination
1. Precision test
And (3) taking the same test sample solution, measuring according to the method, carrying out continuous sample introduction for 6 times, recording a chromatogram, and calculating the relative retention time RSD value of each characteristic peak, wherein the RSD value is less than 1.0%, and the instrument precision is good. The results are shown in Table 3.
TABLE 1 precision test results
2. Repeatability test
Taking the same batch of test samples, preparing 6 test sample solutions according to the method, and measuring, wherein the RSD value of each characteristic peak in 6 times of measurement chromatogram is less than 1.0 percent, which shows that the method has good repeatability. The results are shown in Table 2.
TABLE 2 results of the repeatability tests
3. Stability test
And (3) taking the same test sample solution, and detecting according to the method at 0 hour, 2 hours, 4 hours, 8 hours, 12 hours, 18 hours and 24 hours respectively, wherein the relative retention time RSD value of each characteristic peak is less than 1.0 percent, which indicates that the test sample solution is stable within 24 hours. The results are shown in Table 3.
TABLE 3 solution stability test results
4. Feature mapping
The method is adopted to measure 10 batches of the liver-gallbladder clearing oral liquid, the characteristic spectrum is recorded, the relative retention time is compared, and the result shows that the RSD value of the 10 batches of the liver-gallbladder clearing oral liquid is less than 3.0 percent, and the detailed result is as follows:
TABLE 4
The characteristic spectrum and common mode of 10 batches of Gandanshuangqing oral liquid are obtained by adopting the analysis of 2004A edition of the national pharmacopoeia Committee 'evaluation system of traditional Chinese medicine chromatogram fingerprint spectrum similarity', and are shown in figure 1. Similarity calculation is carried out on the 10 batches of the liver-gallbladder double-clear oral liquid, and the similarity between the 10 batches of the liver-gallbladder double-clear oral liquid and the standard characteristic spectrum is more than 0.90. The detailed results are as follows:
TABLE 5
Establishing 10 batches of HPLC characteristic spectrums of the liver-gallbladder double-clear oral liquid, and analyzing by adopting 2004A edition of 'Chinese medicine chromatogram fingerprint similarity evaluation system' of the State Committee of pharmacopoeia to obtain a standard HPLC characteristic spectrum of the liver-gallbladder double-clear oral liquid consisting of 15 characteristic peaks. The No. 1 peak is gallic acid, the No. 5 peak is paeoniflorin, the No. 6 peak is linalool, the No. 8 peak is ferulic acid, the No. 11 peak is scutellarin, the No. 12 (S) peak is specnuezhenide, and the No. 15 peak is paeonol. The 15 characteristic peaks were assigned: the chromatographic peaks belonging to the tree peony bark are 4, namely peaks 1, 4, 5 and 15; the chromatographic peaks belonging to the sculellaria barbata are 3, namely No. 9, No. 10 and No. 11 peaks respectively; the chromatographic peaks belonging to the glossy privet fruit are 3, namely No. 12, No. 13 and No. 14 peaks respectively; the chromatographic peaks attributed to angelica sinensis are 1, and are No. 8 peaks; the chromatographic peaks attributed to eaglewood are 2 peaks, namely, 6 peaks and 7 peaks.
Comparative example 1:
chromatographic conditions and System suitability test Shimadzu VP-ODS C18 chromatographic column (250 mm. times.4.6 mm, 5 μm); taking methanol-0.4% phosphoric acid aqueous solution (60:40) as a mobile phase; a detection side wavelength of 274 nm; the column temperature is 25 ℃;
preparation of reference solution A proper amount of gallic acid, paeoniflorin, paeonol, ferulic acid, scutellarin, specnuezhenide, and linalool reference substances are precisely weighed, and are respectively prepared into 0.1mg solution per 1mL with methanol.
Preparation of test solution 20mL of the product is precisely measured, placed in a 25mL measuring flask, diluted to scale with water, shaken, filtered, and a subsequent filtrate is taken as the test solution.
The determination method comprises precisely sucking 10 μ L of reference solution and sample solution respectively, injecting into liquid chromatograph, determining, and recording chromatogram.
As a result, the chromatogram has a small number of chromatographic peaks, the chromatographic peaks of the reference substance solution are separated from each other by a difference in resolution, only the paeonol reference substance has a corresponding chromatographic peak, and the other reference substances have no peak.
Comparative example 2:
chromatographic conditions and system applicability test: a Wondacract ODS C18 column (25 cm column length, 4.6mm inner diameter, 5 μm particle size) was used; the mobile phase is A: acetonitrile and B: 0.1 percent phosphoric acid aqueous solution, and the mobile phase gradient elution conditions are as follows: 0min is 0% acetonitrile, 40min is 50% acetonitrile, 42min is 0% acetonitrile, 50min is 0% acetonitrile; the flow rate is 1.0 mL/min; the detection wavelength is 230 nm; the column temperature was 30 ℃.
Preparation of reference solution A proper amount of gallic acid, paeoniflorin, paeonol, ferulic acid, scutellarin, specnuezhenide, and linalool reference substances are precisely weighed, and are respectively prepared into 0.1mg solution per 1mL with methanol.
Preparation of test solution 20mL of the product is precisely measured, placed in a 25mL measuring flask, diluted to scale with water, shaken, filtered, and a subsequent filtrate is taken as the test solution.
The determination method comprises precisely sucking 10 μ L of reference solution and sample solution respectively, injecting into liquid chromatograph, determining, and recording chromatogram.
As a result, the separation degree and asymmetry between the peaks in the chromatogram are low, and the separation effect is poor.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (10)
1. A method for constructing an HPLC (high Performance liquid chromatography) characteristic spectrum of an oral liquid for treating liver and gallbladder diseases is characterized by comprising the following steps of:
measuring the test solution and the reference solution by high performance liquid chromatography;
the conditions of the high performance liquid chromatography are as follows: a C18 chromatography column; taking acetonitrile as a mobile phase A, and taking a phosphoric acid aqueous solution with the mass percentage of 0.05% -0.15% as a mobile phase B, and performing gradient elution; the procedure for the gradient elution was:
2. the construction method according to claim 1, wherein the mobile phase B is a 0.1% phosphoric acid aqueous solution by mass.
3. The method according to claim 1, wherein the C18 chromatographic column has a column length of 25cm, an inner diameter of 4.6mm, and a particle size of 5 μm.
4. The method of claim 1, wherein the C18 column is a Wondacract ODS C18 column.
5. The construction method according to claim 1, wherein the detection wavelength of the high performance liquid chromatography is 230-260 nm.
6. The construction method according to claim 1, wherein the column temperature of the high performance liquid chromatography is 30 to 40 ℃.
7. The construction method according to claim 1, wherein the flow rate of the high performance liquid chromatography is 0.9-1.1 mL/min; the sample volume of the reference substance solution or the test sample solution is 5-15 mu L.
8. The method of claim 1, wherein the reference solution comprises gallic acid solution, paeoniflorin solution, paeonol solution, ferulic acid solution, scutellarin solution, specnuezhenide solution, and linalool solution.
9. The construction method according to claim 8, wherein the solvent of the reference solution is methanol, and the mass volume percentage concentration of the reference solution is 0.08-0.12 mg/mL.
10. The method for constructing according to any one of claims 1 to 9, wherein the sample solution is stock solution of Gandanshuangqing oral liquid or diluted solution of Gandanshuangqing oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910496854.6A CN110118841B (en) | 2019-06-10 | 2019-06-10 | Method for constructing HPLC (high Performance liquid chromatography) characteristic spectrum of liver and gallbladder clearing oral liquid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910496854.6A CN110118841B (en) | 2019-06-10 | 2019-06-10 | Method for constructing HPLC (high Performance liquid chromatography) characteristic spectrum of liver and gallbladder clearing oral liquid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110118841A CN110118841A (en) | 2019-08-13 |
| CN110118841B true CN110118841B (en) | 2021-06-04 |
Family
ID=67524040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910496854.6A Active CN110118841B (en) | 2019-06-10 | 2019-06-10 | Method for constructing HPLC (high Performance liquid chromatography) characteristic spectrum of liver and gallbladder clearing oral liquid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110118841B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112858495A (en) * | 2020-12-02 | 2021-05-28 | 吉林修正药业新药开发有限公司 | Construction method of HPLC (high Performance liquid chromatography) characteristic spectrum of bear gall Keming tablets |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709320A (en) * | 2005-06-14 | 2005-12-21 | 吉林长白山药业集团股份有限公司 | Oral liquid for clearing liver and gallbladder |
-
2019
- 2019-06-10 CN CN201910496854.6A patent/CN110118841B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709320A (en) * | 2005-06-14 | 2005-12-21 | 吉林长白山药业集团股份有限公司 | Oral liquid for clearing liver and gallbladder |
Non-Patent Citations (2)
| Title |
|---|
| A bio-activity guided in vitro pharmacokinetic method to improve the quality control of Chinese medicines, application to SiWu Tang;Ling Wang et al.;《International Journal of Pharmaceutics》;20110108;第99-105页 * |
| 肝胆双清口服液中丹皮酚的HPLC测定;严铭铭 等;《中国药师》;20061231;第241-242页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110118841A (en) | 2019-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105486771B (en) | The fingerprint atlas detection method of Xiao Chai Hu granules compound preparation | |
| CN109633001B (en) | Fingerprint detection method of wine glossy privet fruit | |
| CN109406645A (en) | A kind of Antisathmatic oral liquid for child epheday intermedia, the detection method for frying semen armeniacae amarae, Radix Glycyrrhizae, radix scutellariae | |
| CN108362790B (en) | Method for constructing HPLC (high Performance liquid chromatography) characteristic spectrum of Chinese patent medicine' Qingyidan granules | |
| CN106353430A (en) | Qianliexin capsule quality evaluation method based on multi-index active ingredient measurement | |
| CN111487344B (en) | Method for detecting fingerprint spectrum of motherwort particles | |
| CN111537630A (en) | Method for establishing HPLC fingerprint spectrum and multi-index quantification of gynecological reconstruction pill | |
| CN110118841B (en) | Method for constructing HPLC (high Performance liquid chromatography) characteristic spectrum of liver and gallbladder clearing oral liquid | |
| CN112730674B (en) | Quality detection method of momordica grosvenori tea | |
| CN107576739B (en) | HPLC fingerprint detection method of Longmu Zhuanggu granules | |
| CN113960203A (en) | Method for detecting characteristic spectrum of tianlong formula particles | |
| CN110031564B (en) | Quality detection method of natural plant anticoccidial feed additive based on HPLC fingerprint | |
| CN107782811B (en) | Detection method of fingerprint of Qiling kidney-invigorating tablet | |
| CN104655748B (en) | A kind of erigeron breviscapus granule finger-print and its method for building up and application | |
| CN111855867B (en) | Method for establishing characteristic spectrum of traditional Chinese medicine or traditional Chinese medicine composition preparation and application | |
| CN108663440A (en) | Callicarpa nudiflora medicinal material UPLC fingerprint map constructions method and standard finger-print | |
| CN105699581B (en) | The construction method and its standard finger-print of the UPLC finger-print of sweet clover medicinal material | |
| CN114965802B (en) | Quality control method of climacteric syndrome relieving tablet | |
| CN114216980B (en) | Method for establishing HPLC-ELSD fingerprint of starwort root | |
| CN106442834A (en) | Method for constructing HPLC characteristic spectra of kidney-tonifying nerve-calming drug | |
| CN113391005B (en) | High performance liquid detection method and identification method for garden burnet and garden burnet charcoal decoction pieces, reference extracts and formula granules | |
| CN109828064A (en) | A kind of HPLC fingerprint image method for building up of Heiguteng exract effective part group | |
| CN110031577B (en) | Quality detection method and identification application of traditional Chinese medicine or traditional Chinese medicine composition preparation | |
| CN111487351A (en) | Method for detecting fingerprint of blood-activating pain-relieving capsule | |
| CN112782331B (en) | Characteristic spectrum construction method and identification method for lotus node and lotus node charcoal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20210430 Address after: 130103 No. 1369 Shunda Road, Changchun High-tech Zone, Jilin Province Applicant after: JILIN XIUZHENG PHARMACEUTICAL NEW MEDICINE DEVELOPMENT Co.,Ltd. Applicant after: JILIN CHANGBAISHAN PHARMACEUTICAL GROUP Co.,Ltd. Address before: 130012 4-6 / F, amendment building, 1369 Shunda Road, Changchun City, Jilin Province Applicant before: JILIN XIUZHENG PHARMACEUTICAL NEW MEDICINE DEVELOPMENT Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |